@immucan.bsky.social
Projects end, but their impact continues. As #IMMUcan concludes after 7 years, we reflect on key lessons: adaptability, strong collaboration, high-quality data from day one, and the importance of trust behind every dataset. Explore the project's legacy: www.immucan.eu
June 30, 2026 at 12:21 PM
Projects end, but their impact continues. As #IMMUcan concludes after 7 years, we reflect on key lessons: adaptability, strong collaboration, high-quality data from day one, and the importance of trust behind every dataset. Explore the project's legacy: www.immucan.eu
One of IMMUcan’s biggest achievements is now a reality: a major cancer molecular profiling resource. Over 7 years, researchers generated 3,000+ WES and 2,600+ RNA-seq profiles from 2,500+ patients, creating a lasting legacy for immuno-oncology research. immucan.eu
June 24, 2026 at 12:56 PM
One of IMMUcan’s biggest achievements is now a reality: a major cancer molecular profiling resource. Over 7 years, researchers generated 3,000+ WES and 2,600+ RNA-seq profiles from 2,500+ patients, creating a lasting legacy for immuno-oncology research. immucan.eu
After more than 7 years of collaboration, discovery and knowledge-sharing, IMMUcan leaves behind a significant scientific legacy.
June 19, 2026 at 10:00 AM
After more than 7 years of collaboration, discovery and knowledge-sharing, IMMUcan leaves behind a significant scientific legacy.
Good morning from Berlin! The final IMMUcan General Assembly starts today.
Over the years, IMMUcan has become one of Europe’s largest efforts to profile the tumour microenvironment across cancers, bringing together a wide community.
Time to take stock and look ahead!
#CancerResearch
Over the years, IMMUcan has become one of Europe’s largest efforts to profile the tumour microenvironment across cancers, bringing together a wide community.
Time to take stock and look ahead!
#CancerResearch
May 12, 2026 at 8:01 AM
Good morning from Berlin! The final IMMUcan General Assembly starts today.
Over the years, IMMUcan has become one of Europe’s largest efforts to profile the tumour microenvironment across cancers, bringing together a wide community.
Time to take stock and look ahead!
#CancerResearch
Over the years, IMMUcan has become one of Europe’s largest efforts to profile the tumour microenvironment across cancers, bringing together a wide community.
Time to take stock and look ahead!
#CancerResearch
A medRxiv preprint uses IMMUcan’s multi-modal NSCLC dataset to link tumour microenvironment features with clinical data.
Read the preprint:
www.medrxiv.org/content/10.1...
Access samples: immucan.eu/how-to-colla...
#TranslationalResearch #NSCLC #CancerImmunology
Read the preprint:
www.medrxiv.org/content/10.1...
Access samples: immucan.eu/how-to-colla...
#TranslationalResearch #NSCLC #CancerImmunology
May 5, 2026 at 10:04 AM
A medRxiv preprint uses IMMUcan’s multi-modal NSCLC dataset to link tumour microenvironment features with clinical data.
Read the preprint:
www.medrxiv.org/content/10.1...
Access samples: immucan.eu/how-to-colla...
#TranslationalResearch #NSCLC #CancerImmunology
Read the preprint:
www.medrxiv.org/content/10.1...
Access samples: immucan.eu/how-to-colla...
#TranslationalResearch #NSCLC #CancerImmunology
MMUcan data are driving methods innovation.
A Cell Reports Methods study presents scalable multimodal imaging workflows built on IMMUcan tissue data.
A Cell Reports Methods study presents scalable multimodal imaging workflows built on IMMUcan tissue data.
March 9, 2026 at 9:55 AM
MMUcan data are driving methods innovation.
A Cell Reports Methods study presents scalable multimodal imaging workflows built on IMMUcan tissue data.
A Cell Reports Methods study presents scalable multimodal imaging workflows built on IMMUcan tissue data.
IMMUcan data contributed to a 2024 Immunity paper on CD4⁺ T cell activation and response to PD-L1/CTLA-4 blockade.
Collaborate: immucan.eu/how-to-colla...
Collaborate: immucan.eu/how-to-colla...
February 17, 2026 at 1:24 PM
IMMUcan data contributed to a 2024 Immunity paper on CD4⁺ T cell activation and response to PD-L1/CTLA-4 blockade.
Collaborate: immucan.eu/how-to-colla...
Collaborate: immucan.eu/how-to-colla...
High-impact cancer research starts with the right samples.
IMMUcan opens access to trial-grade oncology biosamples from ~1,400 patients.
immucan.eu/how-to-colla...
#CancerResearch #ImmunoOncology #Biomarkers #MultiOmics
IMMUcan opens access to trial-grade oncology biosamples from ~1,400 patients.
immucan.eu/how-to-colla...
#CancerResearch #ImmunoOncology #Biomarkers #MultiOmics
February 3, 2026 at 1:57 PM
High-impact cancer research starts with the right samples.
IMMUcan opens access to trial-grade oncology biosamples from ~1,400 patients.
immucan.eu/how-to-colla...
#CancerResearch #ImmunoOncology #Biomarkers #MultiOmics
IMMUcan opens access to trial-grade oncology biosamples from ~1,400 patients.
immucan.eu/how-to-colla...
#CancerResearch #ImmunoOncology #Biomarkers #MultiOmics
As 2025 comes to a close, we're grateful for the progress made through IMMUcan — advancing multi-omics data and deepening our understanding of the tumour microenvironment.
Thank you to all patients, clinicians, researchers & collaborators.
✨ Happy Holidays from the IMMUcan team! ✨
Thank you to all patients, clinicians, researchers & collaborators.
✨ Happy Holidays from the IMMUcan team! ✨
December 19, 2025 at 10:09 AM
As 2025 comes to a close, we're grateful for the progress made through IMMUcan — advancing multi-omics data and deepening our understanding of the tumour microenvironment.
Thank you to all patients, clinicians, researchers & collaborators.
✨ Happy Holidays from the IMMUcan team! ✨
Thank you to all patients, clinicians, researchers & collaborators.
✨ Happy Holidays from the IMMUcan team! ✨
🔬 IMMUcan at #ESMOImmuno25 | Poster Highlight II
Real-world data from early-stage #TNBC show evolving neoadjuvant practice across Europe:
⬇️ anthracyclines
⬆️ carboplatin & immunotherapy
📈 pCR rates, highest with KEYNOTE-522–like regimens and high TIL tumors
👉 www.immucan.eu
Real-world data from early-stage #TNBC show evolving neoadjuvant practice across Europe:
⬇️ anthracyclines
⬆️ carboplatin & immunotherapy
📈 pCR rates, highest with KEYNOTE-522–like regimens and high TIL tumors
👉 www.immucan.eu
December 18, 2025 at 10:57 AM
🔬 IMMUcan at #ESMOImmuno25 | Poster Highlight II
Real-world data from early-stage #TNBC show evolving neoadjuvant practice across Europe:
⬇️ anthracyclines
⬆️ carboplatin & immunotherapy
📈 pCR rates, highest with KEYNOTE-522–like regimens and high TIL tumors
👉 www.immucan.eu
Real-world data from early-stage #TNBC show evolving neoadjuvant practice across Europe:
⬇️ anthracyclines
⬆️ carboplatin & immunotherapy
📈 pCR rates, highest with KEYNOTE-522–like regimens and high TIL tumors
👉 www.immucan.eu
🔬 IMMUcan at #ESMOImmuno25
New multi-omics data from advanced TNBC patients treated with chemo-immunotherapy (SYNERGY & EORTC-1553-SPECTA) highlight how early tumor microenvironment changes shape outcomes.
New multi-omics data from advanced TNBC patients treated with chemo-immunotherapy (SYNERGY & EORTC-1553-SPECTA) highlight how early tumor microenvironment changes shape outcomes.
December 16, 2025 at 10:07 AM
🔬 IMMUcan at #ESMOImmuno25
New multi-omics data from advanced TNBC patients treated with chemo-immunotherapy (SYNERGY & EORTC-1553-SPECTA) highlight how early tumor microenvironment changes shape outcomes.
New multi-omics data from advanced TNBC patients treated with chemo-immunotherapy (SYNERGY & EORTC-1553-SPECTA) highlight how early tumor microenvironment changes shape outcomes.
New IMMUcan preprint on early-stage NSCLC just released.
A major multi-institutional effort. Congrats to all contributors! 👏
www.medrxiv.org/content/10.1...
A major multi-institutional effort. Congrats to all contributors! 👏
www.medrxiv.org/content/10.1...
December 3, 2025 at 10:52 AM
New IMMUcan preprint on early-stage NSCLC just released.
A major multi-institutional effort. Congrats to all contributors! 👏
www.medrxiv.org/content/10.1...
A major multi-institutional effort. Congrats to all contributors! 👏
www.medrxiv.org/content/10.1...
Excited to see the Cellohood preprint out — a big step forward for understanding tumor–immune interactions within IMMUcan.
A great milestone for a strong collaborative effort. Congrats to all co-authors! 👏
🔗 www.biorxiv.org/content/10.1...
A great milestone for a strong collaborative effort. Congrats to all co-authors! 👏
🔗 www.biorxiv.org/content/10.1...
November 20, 2025 at 10:22 AM
Excited to see the Cellohood preprint out — a big step forward for understanding tumor–immune interactions within IMMUcan.
A great milestone for a strong collaborative effort. Congrats to all co-authors! 👏
🔗 www.biorxiv.org/content/10.1...
A great milestone for a strong collaborative effort. Congrats to all co-authors! 👏
🔗 www.biorxiv.org/content/10.1...
Last week, the IMMUcan consortium met at EORTC Brussels (27–28 Oct 2025) for two days of inspiring discussions and data exploration. 💡
Researchers, clinicians & data scientists from across Europe shared results and shaped the next steps in cancer-immune research.
Researchers, clinicians & data scientists from across Europe shared results and shaped the next steps in cancer-immune research.
November 3, 2025 at 9:56 AM
Last week, the IMMUcan consortium met at EORTC Brussels (27–28 Oct 2025) for two days of inspiring discussions and data exploration. 💡
Researchers, clinicians & data scientists from across Europe shared results and shaped the next steps in cancer-immune research.
Researchers, clinicians & data scientists from across Europe shared results and shaped the next steps in cancer-immune research.
IMMUcan represents collaboration in action.
Clinicians & researchers across Europe are building one of the largest tumour–immune profiling efforts to date.
Together, we’re turning complexity into impact.
Learn more about our consortium: immucan.eu
Clinicians & researchers across Europe are building one of the largest tumour–immune profiling efforts to date.
Together, we’re turning complexity into impact.
Learn more about our consortium: immucan.eu
October 24, 2025 at 11:08 AM
IMMUcan represents collaboration in action.
Clinicians & researchers across Europe are building one of the largest tumour–immune profiling efforts to date.
Together, we’re turning complexity into impact.
Learn more about our consortium: immucan.eu
Clinicians & researchers across Europe are building one of the largest tumour–immune profiling efforts to date.
Together, we’re turning complexity into impact.
Learn more about our consortium: immucan.eu
Spatial transcriptomics = gene activity + location.
In IMMUcan, it shows where tumour & immune cells interact, and how that shapes treatment response. A living map of the tumour microenvironment.
In IMMUcan, it shows where tumour & immune cells interact, and how that shapes treatment response. A living map of the tumour microenvironment.
October 10, 2025 at 11:20 AM
Spatial transcriptomics = gene activity + location.
In IMMUcan, it shows where tumour & immune cells interact, and how that shapes treatment response. A living map of the tumour microenvironment.
In IMMUcan, it shows where tumour & immune cells interact, and how that shapes treatment response. A living map of the tumour microenvironment.
We’re happy to announce that IMMUcan will be showcased at #EPFCongress2025 (26–27 Nov, Brussels)!
Two days of dialogue on patient involvement, equity, resilience, digital health, AMR, and climate & health.
👉 epfcongress.eu
#PatientLeadership
Two days of dialogue on patient involvement, equity, resilience, digital health, AMR, and climate & health.
👉 epfcongress.eu
#PatientLeadership
October 4, 2025 at 10:38 AM
We’re happy to announce that IMMUcan will be showcased at #EPFCongress2025 (26–27 Nov, Brussels)!
Two days of dialogue on patient involvement, equity, resilience, digital health, AMR, and climate & health.
👉 epfcongress.eu
#PatientLeadership
Two days of dialogue on patient involvement, equity, resilience, digital health, AMR, and climate & health.
👉 epfcongress.eu
#PatientLeadership
Next week, Henoch Hong brings IMMUcan’s voice to London for the Biomarkers + Precision Medicine 2025 Conference (30 Sept – 1 Oct).
Henoch will share how IMMUcan’s pan-European effort to map immune-oncology biomarkers is driving collaboration to unlock new therapies and deliver personalised care.
Henoch will share how IMMUcan’s pan-European effort to map immune-oncology biomarkers is driving collaboration to unlock new therapies and deliver personalised care.
September 26, 2025 at 8:04 AM
Next week, Henoch Hong brings IMMUcan’s voice to London for the Biomarkers + Precision Medicine 2025 Conference (30 Sept – 1 Oct).
Henoch will share how IMMUcan’s pan-European effort to map immune-oncology biomarkers is driving collaboration to unlock new therapies and deliver personalised care.
Henoch will share how IMMUcan’s pan-European effort to map immune-oncology biomarkers is driving collaboration to unlock new therapies and deliver personalised care.
New publication alert in Cell Reports Methods!
The IMMUcan consortium is proud to present our latest work on scalable pipelines for large-scale multiplexed imaging (mIF & IMC) in FFPE tumour tissues.
Congratulations to the authors and contributors!
Read the article www.cell.com/cell-reports...
The IMMUcan consortium is proud to present our latest work on scalable pipelines for large-scale multiplexed imaging (mIF & IMC) in FFPE tumour tissues.
Congratulations to the authors and contributors!
Read the article www.cell.com/cell-reports...
September 12, 2025 at 9:06 AM
New publication alert in Cell Reports Methods!
The IMMUcan consortium is proud to present our latest work on scalable pipelines for large-scale multiplexed imaging (mIF & IMC) in FFPE tumour tissues.
Congratulations to the authors and contributors!
Read the article www.cell.com/cell-reports...
The IMMUcan consortium is proud to present our latest work on scalable pipelines for large-scale multiplexed imaging (mIF & IMC) in FFPE tumour tissues.
Congratulations to the authors and contributors!
Read the article www.cell.com/cell-reports...
What if we could predict a tumour’s next move?
IMMUcan’s deep look into the tumour microenvironment shows how cancer hides, adapts, resists. Every insight brings us closer to smarter, more resilient therapies.
IMMUcan’s deep look into the tumour microenvironment shows how cancer hides, adapts, resists. Every insight brings us closer to smarter, more resilient therapies.
September 2, 2025 at 11:34 AM
What if we could predict a tumour’s next move?
IMMUcan’s deep look into the tumour microenvironment shows how cancer hides, adapts, resists. Every insight brings us closer to smarter, more resilient therapies.
IMMUcan’s deep look into the tumour microenvironment shows how cancer hides, adapts, resists. Every insight brings us closer to smarter, more resilient therapies.
How do cancers evade the immune system?
IMMUcan is helping decode the mechanisms (antigen presentation loss, immune suppression, dynamic resistance) through spatial & single-cell tech.
Understanding this is key to improving immunotherapy.
IMMUcan is helping decode the mechanisms (antigen presentation loss, immune suppression, dynamic resistance) through spatial & single-cell tech.
Understanding this is key to improving immunotherapy.
August 26, 2025 at 9:55 AM
How do cancers evade the immune system?
IMMUcan is helping decode the mechanisms (antigen presentation loss, immune suppression, dynamic resistance) through spatial & single-cell tech.
Understanding this is key to improving immunotherapy.
IMMUcan is helping decode the mechanisms (antigen presentation loss, immune suppression, dynamic resistance) through spatial & single-cell tech.
Understanding this is key to improving immunotherapy.
What if we could decode what’s happening inside a tumour?
IMMUcan has profiled 2,600+ samples across cancer types using multi-omics tech.
We’re mapping how immune & #cancer cells interact, and what signals shape response or resistance.
We aim to predict what #treatment works for each patient.
IMMUcan has profiled 2,600+ samples across cancer types using multi-omics tech.
We’re mapping how immune & #cancer cells interact, and what signals shape response or resistance.
We aim to predict what #treatment works for each patient.
August 19, 2025 at 9:35 AM
What if we could decode what’s happening inside a tumour?
IMMUcan has profiled 2,600+ samples across cancer types using multi-omics tech.
We’re mapping how immune & #cancer cells interact, and what signals shape response or resistance.
We aim to predict what #treatment works for each patient.
IMMUcan has profiled 2,600+ samples across cancer types using multi-omics tech.
We’re mapping how immune & #cancer cells interact, and what signals shape response or resistance.
We aim to predict what #treatment works for each patient.
In cancer research, personalised medicine is a shift in how we understand disease, deliver care, and define outcomes.
We broke it down in this blog: from biomarkers + big data to what matters most: the patient.
Worth a revisit as IMMUcan’s data continues to grow.
bit.ly/4oyKJpx
We broke it down in this blog: from biomarkers + big data to what matters most: the patient.
Worth a revisit as IMMUcan’s data continues to grow.
bit.ly/4oyKJpx
August 8, 2025 at 8:34 AM
In cancer research, personalised medicine is a shift in how we understand disease, deliver care, and define outcomes.
We broke it down in this blog: from biomarkers + big data to what matters most: the patient.
Worth a revisit as IMMUcan’s data continues to grow.
bit.ly/4oyKJpx
We broke it down in this blog: from biomarkers + big data to what matters most: the patient.
Worth a revisit as IMMUcan’s data continues to grow.
bit.ly/4oyKJpx
Did you know? IMMUcan has profiled 2,600+ tumour samples using multi-omics tech: RNA-seq, proteomics, IHC.
Why? To map the tumour microenvironment in detail.
The goal: smarter, personalised immunotherapy for every patient.
Why? To map the tumour microenvironment in detail.
The goal: smarter, personalised immunotherapy for every patient.
August 1, 2025 at 10:46 AM
Did you know? IMMUcan has profiled 2,600+ tumour samples using multi-omics tech: RNA-seq, proteomics, IHC.
Why? To map the tumour microenvironment in detail.
The goal: smarter, personalised immunotherapy for every patient.
Why? To map the tumour microenvironment in detail.
The goal: smarter, personalised immunotherapy for every patient.
IMMUcan at major oncology congresses in 2025!
July 25, 2025 at 3:02 PM
IMMUcan at major oncology congresses in 2025!